Immunohistochemical Evaluation of Ki-67 and Comparison with Clinicopathologic Factors in Breast Carcinomas

Aman, Nguiessan Alphonse; Doukouré, Brahima; Koffi, K; Koui, Baumaney Sylvanus; Traore, Zié Cheick; Kouyaté, M.; Toure, Ibrahiman; Effi, Ahoua Benjamin

doi:10.31557/apjcp.2019.20.1.73

Cited by 38 publications

(24 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, cases with ER negative or PR negative status had higher mean Ki-67 scores. Our results are in accordance with those revealed by some others that investigated Ki-67 as a continuous variable in breast cancer [ 40 , 42 , 46 , 54 ].…”

Section: Discussionsupporting

confidence: 93%

Immunohistochemical expression of substance P in breast cancer and its association with prognostic parameters and Ki-67 index

et al. 2021

View full text Add to dashboard Cite

Background The neuropeptide substance P is a potential biomarker and therapeutic target in cancer. The main objectives of this study were to investigate the expression level of substance P in different breast cancer molecular subtypes and identify its association with clinicopathological parameters of patients and with Ki-67 index. Methods A retrospective analysis was performed for a total of 164 paraffin-embedded breast cancer tissue samples [42 Her2/neu-enriched, 40 luminal A, 42 luminal B (triple-positive) and 40 triple negative subtypes]. The tissue microarray slides containing specimens were used to determine the expression of substance p and Ki-67 by immunohistochemical staining. Results The mean age of the cohort was 51.35 years. Twenty two percent of cases had low substance P expression levels (TS ≤ 5), while 78% had high expression levels (TS > 5). A significant association was found between SP expression level and breast cancer molecular subtype (p = 0.002), TNM stage (p = 0.034), pN stage (p = 0.013), axillary lymph node metastasis (p = 0.004), ER and PR statuses (p<0.001) and history of DCIS (p = 0.009). The average percentage of Ki-67 expression was 27.05%. When analyzed as a continuous variable, significant differences were observed between the mean Ki-67 scores and molecular subtype (p = 0.001), grade (p = 0.003), pN stage (p = 0.007), axillary lymph node metastasis (p = 0.001), and ER and PR statuses (p <0.001). Conclusion SP is overexpressed in most of the analyzed tissues and has a negative prognostic value in the breast cancer patients. Besides substance P is a potential therapeutic target in breast cancer.

show abstract

Section: Discussionsupporting

confidence: 93%

Immunohistochemical expression of substance P in breast cancer and its association with prognostic parameters and Ki-67 index

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This result was similar to other previous studies done by Ayad et al. [18] ; Soliman et al [19] ; Rakha et al [20] ; Pierga et al [21] ; and Aman et al [22] . In our study, 49 (61.25%) cases have tumor-size 2 to 5 cm, 22(27.50%) cases have tumor, size >5 cm, 9 (11.25%) cases have tumor-size less than 2 cm.…”

Section: Discussionsupporting

confidence: 93%

Study of Ki-67 Immunostaining in Breast Carcinoma and it’s Correlation with Grade of Tumor and Lymph Node

Singh¹,

Sachan²,

Verma³

et al. 2019

SSR-IIJLS

View full text Add to dashboard Cite

Background: Breast cancer is the commonest cancer in women worldwide and represents a disease with wide spectrum particularly in terms of tumour histology, biology, prognosis and response to therapy. Breast cancer is characterized by cellular heterogeneity. Methods: The study was conducted in the Department of Pathology, GSVM Medical College, Kanpur and associated hospital of Kanpur from January 2018 to September 2019 on patients of breast carcinoma. These cases were selected from the outpatient and inpatient of LLR Hospital, Kanpur, India. In the present study, we had taken a total of 80 cases of invasive breast carcinoma as well as Histomorphology, Ki-67 immunostaining and it's a correlation with lymph node status and tumour grade were studied. Results: This study leads us to conclude that the peak incidence of invasive breast carcinoma was reported in the age group of 41 to 50 years (with mean age 47.32 year and the standard deviation was 11.63). In the present study, the most common histological type was invasive ductal carcinoma, not otherwise specified (NOS). In our study, 66.25% of cases had metastatic lymph nodes and half of them were having more than 4 metastatic lymph node. In the grade-II of Bloom Richardson Grading system, there were 40% cases and in grade-III there were 35% of cases and grade-I has shown 25% of cases. A significant association was found between the grade of the tumor and the lymph node positivity. Conclusion: The present study concluded a positive correlation between the grade of tumour and Ki-67 immunohistochemistry, which was used as a prognostic and predictive parameter.

show abstract

“…Combination of chemotherapy with immunotherapy, as in this study, has also been shown by previous studies [8][9][10] to enhance survival of patients.…”

Section: Discussionsupporting

confidence: 81%

“…Immunotherapy has proved to be of great advantage in the treatment of metastatic breast carcinoma, especially when combined with chemotherapy [7][8][9][10], as well as in the treatment of metastatic colorectal carcinoma and hepatocellular carcinoma [10].…”

Section: Introductionmentioning

confidence: 99%

Selecting patients for treatment with immunotherapy: Our experience in a resource-deprived economy

Chianakwana¹,

Egwuonwu²,

Okoli³

et al. 2020

Int J Immunother Cancer Res

View full text Add to dashboard Cite

Background: Majority of the solid cancer patients seen in our Centers come with advanced diseases. Some of the cancers are locally advanced, while others are metastatic. Most of these patients who present late belong to the poverty-stricken group in our community. Only few of them can afford costly drugs for their treatment. The government Health Insurance Scheme does not cover cancer patients in Nigeria. Aim: To highlight the importance of immunotherapy in the management of metastatic cancers. Objective: We wish to share our experience in the use of immunotherapy (Bevacizumab) for metastatic cancers in the few patients who could afford the drug, and to highlight the need for reduction of the prices of immunotherapeutic drugs, or for government to subsidize the costs. Methods: From the 1,135 solid cancer patients treated in our two Centers in three years (February 2017 to January 2020), those who presented with metastasis were slated for immunotherapy after we had obtained their immunohistochemistry results. Results: Six hundred and one (601) patients (53.0%) presented late. Three hundred and fi ve (305) of these late presenters (50.7%) came with metastasis. Only 67 (22.0%) out of the 305 metastatic patients could afford immunotherapy, because of high cost. With the exception of one female patient, each of the remaining 66 patients was able to afford only one single dose of Bevacizumab (Avastin) R. Of these patients, one died of Tumor Lysis Syndrome following one single dose of 600 mg of Bevacizumab. There were measurable shrinkages of the tumor burdens, as well as improvement in the quality of life of the remaining 66 patients. Conclusion: Following these encouraging results, immunotherapy for metastatic carcinomas is to be encouraged for wider use, even in resource-deprived economies. Repeated doses will offer the patient greater benefi ts. Government should subsidize the cost of immunotherapeutic drugs so that they would become affordable by majority of those who need them.

show abstract

Immunohistochemical Evaluation of Ki-67 and Comparison with Clinicopathologic Factors in Breast Carcinomas

Cited by 38 publications

References 36 publications

Immunohistochemical expression of substance P in breast cancer and its association with prognostic parameters and Ki-67 index

Immunohistochemical expression of substance P in breast cancer and its association with prognostic parameters and Ki-67 index

Study of Ki-67 Immunostaining in Breast Carcinoma and it’s Correlation with Grade of Tumor and Lymph Node

Selecting patients for treatment with immunotherapy: Our experience in a resource-deprived economy

Contact Info

Product

Resources

About